Paper - WANFANG MED ONLINE

You Position: Home > Paper

胰腺癌分子分型及其潜在临床应用

( views:310, downloads:217 )

Author:: No author available

Journal Title:: Chinese Journal of Pancreatology

Issue:: 4

DOI:: 10.3760/cma.j.issn.1674-1935.2019.04.017

Key Word:: 胰腺癌;分子亚型;治疗;预后

Abstract：胰腺癌恶性程度高、预后差、发病率逐年上升.由于胰腺癌异质性的存在,一系列研究对胰腺癌进行了分子分型,以期能够为胰腺癌的临床治疗和预后提供更精准的帮助.本文就近年来胰腺癌分子分型、不同亚型的治疗及预后进行综述.

Reference

[1]Dung-Tsa, Chen,Ashley H, Davis-Yadley,Po-Yu, Huang,etc.Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.[J].2015,10(8).
[2]Agnieszka Anna Rucki,Lei ZHENG.Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies[J].2014,(9).
[3]Muckenhuber, Alexander,Berger, Anne Katrin,Schlitter, Anna Melissa,etc.Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response[J].2018,24(2).
[4]Pillarisetty, Venu G..The pancreatic cancer microenvironment: an immunologic battleground[J].2014,3(8).
[5]Moffitt, Richard A.,Marayati, Raoud,Flate, Elizabeth L.,etc.Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma[J].2015,47(10).
[6]Peter, Bailey,David K, Chang,Katia, Nones,etc.Genomic analyses identify molecular subtypes of pancreatic cancer.[J].2016.
[7]Sam S, Chang.Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer.[J].2015,194(4).
[8]Haluska FG,Louis DN,Christiani DC,etc.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.[J].2004,350(21).
[9]Benjamin Bian,Martin Bigonnet,Odile Gayet,etc.Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts[J].2017,9(4).
[10]Wigginton,J.M.,Brahmer,J.R.,McDonald,D.,etc.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J].2012,366(26).
[11]Heinemann,V.,Reni,M.,Ychou,M.,etc.Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies[J].2014,40(1).
[12]Collisson EA,Sadanandam A,Olson P,etc.Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.[J].2011,17(4).
[13]Birnbaum, David J.,Finetti, Pascal,Lopresti, Alexia,etc.A 25-gene classifier predicts overall survival in resectable pancreatic cancer.[J].2017,15.
[14]Leong, Chee-Onn,Hii, Ling-Wei,Mai, Chun Wai,etc.Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC)[J].2018,23(5).
[15]Waghray,M.,Yalamanchili,M.,Magliano,M.P.D.,etc.Deciphering the role of stroma in pancreatic cancer[J].2013,29(5).
[16]David J, Birnbaum,Pascal, Finetti,Daniel, Birnbaum,etc.Validation and comparison of the molecular classifications of pancreatic carcinomas.[J].2017,16(1).
[17]Duconseil, Pauline,Gilabert, Marine,Gayet, Odile,etc.Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma[J].2015,185(4).
[18]Gerlinger,M.,Rowan,A.J.,Horswell,S.,etc.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J].2012,366(10).
[19]Wang, Bolun,Huang, Jingcao,Wang, Shuiliang,etc.Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer[J].2018,420.
[20]Knudsen, Erik S.,Vail, Paris,Balaji, Uthra,etc.Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers[J].2017,23(15).